Table III.
WBC Counts Following Treatment with the Combination Therapy
| Tumor type | Treatment | White blood cell count (x109 cells/L) | ||
|---|---|---|---|---|
| Basal | Day 14 | Day 28 | ||
| SKOV3TR | Control | 2.16 ± 0.24 | 2.51 ± 0.34 | 3.02 ± 0.46 |
| PTX (S) | 2.78 ± 0.58 | 2.98 ± 0.38 | 2.58 ± 0.25 | |
| PTX (NP) | 3.07 ± 0.35 | 2.530 ± 0.59 | 3.25 ± 0.25 | |
| PTX + CER (S) | 1.87 ± 0.26 | 3.12 ± 0.48 | 2.64 ± 0.23 | |
| PTX + CER (NP) | 2.42 ± 0.42 | 2.70 ± 0.25 | 2.54 ± 0.34 | |
| MCF7TR | Control | 2.83 ± 0.28 | 3.81 ± 0.974 | 2.83 ± 0.52 |
| PTX (S) | 2.22 ± 0.58 | 3.32 ± 0.89 | 3.17 ± 0.96 | |
| PTX (NP) | 3.94 ± 0.40 | 4.79 ± 1.02 | 5.32 ± 1.44 | |
| PTX + CER (S) | 2.85 ± 0.43 | 3.20 ± 0.31 | 3.01 ± 0.41 | |
| PTX + CER (NP) | 2.72 ± 0.76 | 2.97 ± 0.35 | 3.17 ± 0.77 | |
Average WBC count at basal, day 14, and day 28 after treatment with 20 mg/kg PTX and/or 80 mg/kg CER in solution or in polymer-blend nanoparticles as a measure of toxicity in mice bearing SKOV3TR ovarian adenocarcinoma and MCF7TR breast adenocarcinoma tumors. control indicates no treatment. (n = 4 mice per treatment per tumor type)
PTX paclitaxel, CER C6-ceramide, S solution, NP nanoparticles